Oxford-based Immunocore Holdings, a clinical-stage T cell receptor biotech company, last week priced an upsized US$350m 2.50% convertible senior 144a notes issue due 2030 in a private offering to qualified…
UK: Immunocore prices upsized convertible notes
…
…






